CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett's esophagus.
Animal models
Barrett’s esophagus
CXCR4
Dysplasia
Endoscopy
Esophageal cancer
Fluorescence imaging
Molecular imaging
Peptide
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
10 Jan 2022
10 Jan 2022
Historique:
received:
12
10
2021
accepted:
24
12
2021
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
11
1
2022
Statut:
epublish
Résumé
Near-infrared (NIR) fluorescence imaging has been emerging as a promising strategy to overcome the high number of early esophageal adenocarcinomas missed by white light endoscopy and random biopsy collection. We performed a preclinical assessment of fluorescence imaging and endoscopy using a novel CXCR4-targeted fluorescent peptide ligand in the L2-IL1B mouse model of Barrett's esophagus. Six L2-IL1B mice with advanced stage of disease (12-16 months old) were injected with the CXCR4-targeted, Sulfo-Cy5-labeled peptide (MK007), and ex vivo wide-field imaging of the whole stomach was performed 4 h after injection. Before ex vivo imaging, fluorescence endoscopy was performed in three L2-IL1B mice (12-14 months old) by a novel imaging system with two L2-IL1B mice used as negative controls. Ex vivo imaging and endoscopy in L2-IL1B mice showed that the CXCR4-targeted MK007 accumulated mostly in the dysplastic lesions with a mean target-to-background ratio > 2. The detection of the Sulfo-Cy5 signal in dysplastic lesions and its co-localization with CXCR4 stained cells by confocal microscopy further confirmed the imaging results. This preliminary preclinical study shows that CXCR4-targeted fluorescence endoscopy using MK007 can detect dysplastic lesions in a mouse model of Barrett's esophagus. Further investigations are needed to assess its use in the clinical setting.
Sections du résumé
BACKGROUND
BACKGROUND
Near-infrared (NIR) fluorescence imaging has been emerging as a promising strategy to overcome the high number of early esophageal adenocarcinomas missed by white light endoscopy and random biopsy collection. We performed a preclinical assessment of fluorescence imaging and endoscopy using a novel CXCR4-targeted fluorescent peptide ligand in the L2-IL1B mouse model of Barrett's esophagus.
METHODS
METHODS
Six L2-IL1B mice with advanced stage of disease (12-16 months old) were injected with the CXCR4-targeted, Sulfo-Cy5-labeled peptide (MK007), and ex vivo wide-field imaging of the whole stomach was performed 4 h after injection. Before ex vivo imaging, fluorescence endoscopy was performed in three L2-IL1B mice (12-14 months old) by a novel imaging system with two L2-IL1B mice used as negative controls.
RESULTS
RESULTS
Ex vivo imaging and endoscopy in L2-IL1B mice showed that the CXCR4-targeted MK007 accumulated mostly in the dysplastic lesions with a mean target-to-background ratio > 2. The detection of the Sulfo-Cy5 signal in dysplastic lesions and its co-localization with CXCR4 stained cells by confocal microscopy further confirmed the imaging results.
CONCLUSIONS
CONCLUSIONS
This preliminary preclinical study shows that CXCR4-targeted fluorescence endoscopy using MK007 can detect dysplastic lesions in a mouse model of Barrett's esophagus. Further investigations are needed to assess its use in the clinical setting.
Identifiants
pubmed: 35006394
doi: 10.1186/s13550-021-00875-7
pii: 10.1186/s13550-021-00875-7
pmc: PMC8748556
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 84: B05
Informations de copyright
© 2021. The Author(s).
Références
Oncotarget. 2017 Aug 1;8(50):87095-87106
pubmed: 29152066
Eur J Nucl Med Mol Imaging. 2021 Dec 9;:
pubmed: 34882260
Cancer Res. 2018 Nov 1;78(21):6268-6281
pubmed: 30228173
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57
pubmed: 21680910
Org Lett. 2008 May 15;10(10):2015-8
pubmed: 18407647
Cell Mol Immunol. 2015 Jul;12(4):474-82
pubmed: 25363530
Nat Commun. 2018 Jul 4;9(1):2605
pubmed: 29973582
BMC Cancer. 2006 Dec 18;6:290
pubmed: 17176471
Oncogene. 2012 Nov 8;31(45):4750-8
pubmed: 22266857
Dig Dis Sci. 2018 Aug;63(8):2013-2021
pubmed: 29948557
Endoscopy. 2018 Jun;50(6):618-625
pubmed: 29342490
Curr Gastroenterol Rep. 2012 Jun;14(3):216-25
pubmed: 22453701
ChemMedChem. 2011 Oct 4;6(10):1789-91
pubmed: 21780290
Cancer Cell. 2012 Jan 17;21(1):36-51
pubmed: 22264787
Ann Surg Oncol. 2011 Nov;18(12):3506-13
pubmed: 21509632
Cancers (Basel). 2021 Nov 25;13(23):
pubmed: 34885030
Tumour Biol. 2014 Apr;35(4):3709-15
pubmed: 24326770
J Biomed Opt. 2013 Oct;18(10):101302
pubmed: 23797876
Int J Cancer. 2010 Sep 1;127(5):1180-7
pubmed: 20039317
Sci Rep. 2017 May 31;7(1):2554
pubmed: 28566721
Gastroenterology. 2019 Aug;157(2):492-506.e2
pubmed: 30998992
Clin Cancer Res. 2018 Mar 1;24(5):1048-1061
pubmed: 29208671
J Natl Cancer Inst. 2005 Dec 21;97(24):1840-7
pubmed: 16368946
Lancet. 2009 Mar 7;373(9666):850-61
pubmed: 19269522
Gut. 2019 Jan;68(1):7-10
pubmed: 29247063
Gastroenterol Clin North Am. 2015 Jun;44(2):203-31
pubmed: 26021191
Head Neck Oncol. 2009 Aug 13;1:32
pubmed: 19678942
N Engl J Med. 2011 Oct 13;365(15):1375-83
pubmed: 21995385
J Nucl Med. 2011 Nov;52(11):1803-10
pubmed: 22045709
BMC Cancer. 2008 Nov 23;8:340
pubmed: 19025611
Theranostics. 2020 Jul 9;10(18):8264-8280
pubmed: 32724470